The British Journal of Psychiatry (2006) 189: 213-220. doi: 10.1192/bjp.189.3.213
© 2006 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data supplements
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Voshaar, R. C. O.
Right arrow Articles by Zitman, F. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Voshaar, R. C. O.
Right arrow Articles by Zitman, F. G.

REVIEW ARTICLES

Strategies for discontinuing long-term benzodiazepine use

Meta-analysis

Richard C. Oude Voshaar, MD, PhD

Department of Psychiatry, Radboud University Nijmegen Medical Center, Nijmegen

Jaap E. Couvée, PhD

GlaxoSmithKline, Zeist

Anton J. L. M. Van Balkom, MD, PhD

Department of Psychiatry and Institute for Research and Extramural Medicine, Free University Medical Centre, Amsterdam

Paul G. H. Mulder, PhD

Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam

Frans G. Zitman, MD, PhD

Department of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands

Correspondence: Dr J. E. Couvée, Head Clinical Development CNS, Anti-Infectives and Oncology, GlaxoSmithKline, Medical Department, Huis ter Heideweg 62, 3705 LZ Zeist, The Netherlands. Tel: +31 30 6938145; fax: +31 30 6938459; email: jaap.e.couvee{at}gsk.com

Declaration of interest None.

Background The prevalence of benzodiazepine consumption in European countries remains at 2-3% of the general population despite the well-documented disadvantages of long-term use.

Aims To review systematically the success rates of different benzodiazepine discontinuation strategies.

Method Meta-analysis of comparable intervention studies.

Results Twenty-nine articles met inclusion criteria. Two groups of interventions were identified; minimal intervention (e.g. giving simple advice in the form of a letter or meeting to a large group of people; n=3), and systematic discontinuation (defined as treatment programmes led by a physician or psychologist; n=26). Both were found to be significantly more effective than treatment as usual: minimal interventions (pooled OR=2.8, 95% CI 1.6-5.1); systematic discontinuation alone (one study, OR=6.1, 95% CI 2.0-18.6). Augmentation of systematic discontinuation with imipramine (two studies, OR=3.1, 95% CI 1.1-9.4) or group cognitive-behavioural therapy for patients with insomnia (two studies, OR=5.5, 95% CI 2.3-14.2) was superior to systematic discontinuation alone.

Conclusions Evidence was found for the efficacy of stepped care (minimal intervention followed by systematic discontinuation alone) in discontinuing long-term benzodiazepine use.